Using Early Scientific Advice in Drug Development: Opportunities and Challenges

In Europe, “scientific advice” (SA) refers to an early dialogue between a manufacturer, health technology assessment (HTA) bodies and/or regulators on initial evidence generation for relative effectiveness and cost effectiveness assessments. The SA and parallel scientific advice (PSA) processes are valuable in helping companies to develop evidence that demonstrates the value of their product, to gain detailed feedback on their evidence generation plans, to integrate cost-effectiveness considerations into health technology assessments (HTA) and to better understand the concerns and perspectives of HTA and/or regulatory decision makers.

Manufactures must now also consider the impact of Brexit on existing SA processes. For example, while the UK National Institute for Health and Care Excellence (NICE) is a leader due to the potential applicability of its advice to over 20 countries, it will no longer be able to provide parallel advice with the European Medicines Agency (EMA) through the European Network for Heath Technology Assessment (EUnetHTA) and will have to develop concurrent advice.

Join this webinar to hear experts discuss Brexit impacts and some other challenges manufacturers should prepare for in the future.

Speakers

Celine Taveau, Principal, Global HTA, Health Economics, Reimbursement and Outcomes, ICON plc

Céline Taveau joined ICON in 2008. She is an experienced consultant with over 12 years of market access experience. Taveau provides senior leadership for large projects on strategic market access and Health Technology Assessment (HTA)’s for pharmaceutical, vaccine and medical device companies. She has extensive experience with orphan drugs and has worked on projects for products in a number of oncology indications, immunology, cardiovascular, respiratory and infectiology. Her experience is wide, working on projects for market access strategies, systematic literature reviews, value proposition development, French HTA submissions and payer advisory boards. Taveau holds a keen interest in orphan drugs and has presented at international conferences/workshops on this topic.

Message Presenter

Emmanuel Lacharme, Senior Consultant, Global HTA, Health Economics, Reimbursement and Outcomes, ICON plc

Emmanuel Lacharme joined ICON in May 2020 as a senior consultant. Lacharme is a pharmacist, with more than five years of professional experience in clinical practice, clinical trials, market access (HEOR/HEMA), scientific advice and health technology assessment. During his pharmacy residency, he worked in various Paris hospitals in clinical trials, ATU, medical device, purchase, and clinical pharmacy (psychiatry, neurology) departments. He worked one year at Novartis on market access, pricing and reimbursement in the oncology department. Lacharme also worked for one year at the HAS as a health technology assessment analyst in economic and clinical drug assessment. Lastly, he worked six months as technical leader in the scientific advice department at NICE.

Message Presenter